About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Dallas | 15,003 Studies Near You | Clareo Health

Clinical Trials LocationsDallas

Clinical Trials in Dallas

Discover 15,003 clinical trials near Dallas, Texas. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 2461-2480 of 15,003 trials

COMPLETEDPhase 1/2< 1 mile

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

NCT02362035

This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.

Follicular Lymphoma (FL)CLLSmall Lymphocytic Lymphoma (SLL)+10 more

Acerta Pharma BV161 participantsStarted Feb 2015

Tucson, Arizona, United States • Los Angeles, California, United States • Denver, Colorado, United States +16 more locations

Active Not RecruitingPhase 2< 1 mile

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

NCT06376045

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

Amgen317 participantsStarted May 2024

Bakersfield, California, United States • La Jolla, California, United States • La Palma, California, United States +151 more locations

Find Trials by Condition in Dallas

Breast Cancerin Dallas Lung Cancerin Dallas Prostate Cancerin Dallas Colorectal Cancerin Dallas Melanomain Dallas Leukemiain Dallas Lymphomain Dallas Pancreatic Cancerin Dallas Ovarian Cancerin Dallas Brain Cancerin Dallas Diabetesin Dallas

Data from ClinicalTrials.govTerms

COMPLETEDPhase 3< 1 mile

Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

NCT06153693

This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications.

Mineralys Therapeutics Inc.1,083 participantsStarted Nov 2023

Alexander City, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +181 more locations

COMPLETEDPhase 3< 1 mile

A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence

NCT06387394

The masseter muscle is one of the muscles in the lower face used for chewing. The prominence of the masseter muscle can appear as a widened lower face which some individuals deem as aesthetically undesirable and can be treated by selectively weakening the masseter muscles with small quantities of botulinum toxin. The purpose of this study is to assess how safe and effective injection of onabotulinumtoxinA (BOTOX) is in adult participants with Masseter Muscle Prominence (MMP). BOTOX is being investigated for the treatment of Muscle Masseter Prominence. In Period 1, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment, placebo or BOTOX. There is a 1 in 4 chance that participants will be assigned to placebo. In Period 2, eligible participants can receive an optional open-label retreatment of BOTOX. Approximately 200 adult participants with MMP will be enrolled in the study at approximately 20 sites in the United States. Participants will receive intramuscular injections across both the right and left masseter muscle of either BOTOX or placebo on Day 1. Participants who are eligible for re-treatment will be given BOTOX injections on either the Day 180, 210, 240, or 270 visit and will be followed up for up to 6 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular monthly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects, and completing questionnaires.

Masseter Muscle Prominence

AbbVie202 participantsStarted Apr 2024

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +17 more locations

Active Not RecruitingNA< 1 mile

ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement

NCT03735667

To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR. As of 28-May-2025, Boston Scientific Corporation (BSC) announced the voluntary global discontinuation of the ACURATE product platform, including both the ACURATE neo2 and ACURATE Prime Aortic Valve Systems. BSC will no longer pursue regulatory approval for the device in the U.S. or other unapproved geographies.

Aortic Stenosis

Boston Scientific Corporation1,948 participantsStarted Jun 2019

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Scottsdale, Arizona, United States +72 more locations

RECRUITINGPhase 2< 1 mile

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

NCT06369285

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alisertib and endocrine therapy.

Hormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast CancerRecurrent Breast Cancer

Puma Biotechnology, Inc.150 participantsStarted Nov 2024

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Beverly Hills, California, United States +50 more locations

RECRUITINGPhase 1/29.2 miles

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

NCT06922591

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.

PDACPDAC - Pancreatic Ductal AdenocarcinomaNSCLC+5 more

Tango Therapeutics, Inc.183 participantsStarted May 2025

Scottsdale, Arizona, United States • Denver, Colorado, United States • Jacksonville, Florida, United States +9 more locations

Active Not RecruitingPhase 112 miles

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

NCT06265220

AB-101 (also known as AlloNK) is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that is known to enhance the effect of monoclonal antibody therapies. This clinical trial will enroll adult patients with lupus nephritis Class III or IV either with or without the presence of Class V who relapsed or did not respond to previous standard of care treatment approaches, or other forms of refractory systemic lupus erythematosus. The primary objective is to assess the safety, tolerability and preliminary activity of AB-101 plus a B-cell depleting mAb (e.g., rituximab, obinutuzumab) after cyclophosphamide and fludarabine in adult subjects with relapsed/refractory lupus nephritis Class III or IV, with or without the presence of Class V, or other forms of refractory systemic lupus erythematosus. Patients will be assigned to receive either AB-101 alone as monotherapy or in combination with a B-cell depleting mAb (e.g., rituximab, obinutuzumab). All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and response status. Patients may receive up to 2 cycles of treatment spaced 24 weeks apart.

Lupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IVRefractory Systemic Lupus Erythematosus+1 more

Artiva Biotherapeutics, Inc.51 participantsStarted Apr 2024

Birmingham, Alabama, United States • Tucson, Arizona, United States • San Diego, California, United States +6 more locations

COMPLETEDPhase 312 miles

A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

NCT05628103

This study evaluated how well SEP-363856 works and how safe it is in people with schizophrenia that switch to SEP-363856 from their current antipsychotic medication.

Otsuka Pharmaceutical Development & Commercialization, Inc.101 participantsStarted Dec 2022

Anaheim, California, United States • Bellflower, California, United States • Culver City, California, United States +22 more locations

TERMINATEDPhase 331 miles

Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

NCT05568888

This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, large simple trial to investigate the efficacy and safety of a single intravenous (IV) infusion of BE1116 in subjects who have traumatic injury, with confirmed or suspected acute major bleeding and / or predicted to receive a large volume blood product transfusion.

Traumatic Injury

CSL Behring1,366 participantsStarted Mar 2023

Birmingham, Alabama, United States • Mobile, Alabama, United States • Chandler, Arizona, United States +110 more locations

COMPLETEDPhase 2190 miles

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

NCT01950390

This randomized phase II trial studies how well ipilimumab with or without bevacizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7Unresectable Melanoma

National Cancer Institute (NCI)169 participantsStarted Jan 2014

Birmingham, Alabama, United States • Mobile, Alabama, United States • Anaheim, California, United States +479 more locations

RECRUITINGNA214 miles

Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers

NCT07116876

This study will evaluate Matrion™ (LifeNet Health, Inc., Virginia Beach, VA), a placental membrane product, as a treatment for diabetic foot ulcers compared to conventional wound care. Matrion is derived from donated human birth tissue and includes both the amniotic and chorionic layers, along with the trophoblast layer. It is minimally processed using a proprietary decellularization method and terminally sterilized to ensure the membrane is acellular and sterile, making it suitable for surgical applications.

Diabetic Foot Ulcer (DFU)Lower Extremity

LifeNet Health120 participantsStarted Jun 2025

Tucson, Arizona, United States • Castro Valley, California, United States • Fresno, California, United States +15 more locations

COMPLETEDPhase 3225 miles

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

NCT03615326

The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive gastric cancer. The primary hypotheses of the study are that pembrolizumab plus trastuzumab in combination with chemotherapy is superior to trastuzumab plus chemotherapy in terms of 1) progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), and 2) overall survival (OS).

Gastric NeoplasmsGastroesophageal Junction Adenocarcinoma

Merck Sharp & Dohme LLC738 participantsStarted Oct 2018

Los Angeles, California, United States • Monterey, California, United States • Orange, California, United States +189 more locations

RECRUITINGPhase 1225 miles

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

NCT05602363

This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

B-cell MalignancyChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma+5 more

Carna Biosciences, Inc.120 participantsStarted Aug 2023

Orange, California, United States • Miami Beach, Florida, United States • Tampa, Florida, United States +10 more locations

Active Not RecruitingPhase 3268 miles

INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP

NCT06144840

To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP.

Erythropoietic Protoporphyria (EPP)X-Linked Protoporphyria (XLP)

Tanabe Pharma America, Inc.165 participantsStarted Dec 2023

Huntington Beach, California, United States • San Francisco, California, United States • Miami, Florida, United States +33 more locations

TERMINATEDPhase 2728 miles

A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06028230

This is a parallel, Phase 2, 3-arm study to evaluate the efficacy, safety, PK, and biological effects of SAR444656 compared with placebo in adult participants with moderate to severe HS aged ≥18 to 70 years. Study details include: * Screening period: up to 4 weeks (30 days) * Treatment duration: up to 16 weeks * Follow-up period: up to 4 weeks * Total study duration: up to 24 weeks * Number of visits: 14

Hidradenitis Suppurativa

Sanofi70 participantsStarted Sep 2023

Scottsdale, Arizona, United States • Anaheim, California, United States • Fountain Valley, California, United States +49 more locations

RECRUITINGNA811 miles

Evaluation of A Clinical Diagnostic Test for CRDS

NCT06188689

Calcium Release Deficiency Syndrome (CRDS) is a novel inherited arrhythmia syndrome secondary to RyR2 loss-of-function that confers a risk of sudden cardiac death. Diagnosis of CRDS presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. We hypothesize that CRDS can be diagnosed clinically through evaluation of the repolarization response to brief tachycardia, mediated by cardiac pacing, and a subsequent pause.

Calcium Release Deficiency Syndrome (CRDS)

Population Health Research Institute400 participantsStarted Feb 2023

San Francisco, California, United States • Rochester, Minnesota, United States • Seattle, Washington, United States +15 more locations

TERMINATEDNA912 miles

PACESETTER: Program to Avoid Cerebrovascular Events Through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor

NCT03401489

Program to Avoid Cerebrovascular Events through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor (PACESETTER) aims to assess the incorporation of its stroke intervention into 2 safety net/academic health systems in a given US state especially burdened by stroke, thereby enhancing knowledge about the complexity of stroke interventions, and especially the nature of the challenges encountered in low resource settings and for populations traditionally underrepresented in research. Altogether, the intervention, if proven implementable and effective, may eventually be exported to other medically underserved populations in the US beyond SC as a feasible model of post-stroke management.

Blood PressureHypertensionMhealth

Northern California Institute of Research and Education120 participantsStarted Jul 2020

San Francisco, California, United States • Charleston, South Carolina, United States • Columbia, South Carolina, United States +1 more locations

COMPLETED969 miles

Anal High-risk HPV, HSIL, and Microbiome Among Hispanic Peoples Living With HIV (PLWH)

NCT06651957

The study evaluates if there is relationship between the kinds of bacteria living in the anus (also known as the anal microbiome) and the risk of human papillomavirus (HPV) infection or HPV-related pre-cancer (high-grade squamous intraepithelial lesions or HSIL) in Hispanic people living with HIV (PLWH) in Puerto Rico, Mexico and California

Human Immunodeficiency VirusHuman Papillomavirus-Related Anal Squamous Cell CarcinomaHigh-Grade Squamous Intraepithelial Lesions

University of California, San Francisco217 participantsStarted Oct 2024

San Francisco, California, United States • Cuernavaca, Morelos, Mexico • San Juan, Puerto Rico

RECRUITINGPhase 21110 miles

CapTemY90 for Grade 2/3 NET Liver Metastases

NCT04339036

This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone. A Grade 3 arm was added in 2025.

Neuroendocrine Tumor Grade 2Neuroendocrine Tumors

Abramson Cancer Center at Penn Medicine70 participantsStarted Oct 2021

La Jolla, California, United States • Miami, Florida, United States • Buffalo, New York, United States +1 more locations

PreviousPage 124 of 751Next

Heart Diseasein Dallas